Clinical study on effectiveness and safety of Kunbixiao Decoction optimized by Ersi decoction in the treatment of female rheumatoid arthritis

Xiyuan Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Female RA patients who meet the diagnostic criteria of Western medicine and TCM syndrome of ''Toxin Heat Phlegm Stasis Accumulation Syndrome'';
•2. Aged 18-65 years;
•3. Disease activity score (DAS28) > 3.2 and <= 5.1;
•4. Those who did not participate in any drug trials within 4 weeks before enrollment;
•5. Volunteer subjects and signed informed consent.

•1. Patients who are pregnant, breastfeeding, planning to become pregnant during treatment and/or within 12 weeks after the end of treatment;
•2. Combined with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system, mental patients;
•3. Those who have been diagnosed with other connective tissue diseases such as systemic lupus erythematosus, Sj?gren's syndrome, myositis or dermatomyositis;
•4. There are pituitary tumors, hyperthyroidism, ovarian cysts and other diseases affecting endocrine, history of uterine or ovarian surgery, or oral contraceptives within the past 4 weeks;
•5. Those who do not meet the requirements for combined medication;
•6. Those who are known to be allergic to any traditional Chinese medicine used in this test, or allergic constitution (allergic to two or more drugs, food, and pollen).
•7. Those with a history of drug, drug or alcohol abuse;
•8. Other conditions deemed inappropriate by the investigator.

发起方